OpGen has appointed Tina Nova to its board of directors. Nova currently serves as president and CEO of newly formed molecular diagnostics company Molecular Stethoscope, and most recently served as senior vice president and general manager of Illumina's oncology business unit. From 2000 to 2014, Nova was cofounder, director, president, and CEO of Genoptix Medical Laboratory, which was purchased by Novartis for nearly $500,000 in 2011. She has also held senior positions with Nanogen, Ligand Pharmaceuticals, and Hybritech. She currently serves on the board of Arena Pharmaceuticals and Veracyte, and is vice chairman of the board for the newly formed Rady Pediatric Genomics and Systems Medicine Institute.